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Abstract
HCV infection is a major risk factor for liver cancer and liver transplantation worldwide. Overstimulation of host lipid
metabolism in the liver by HCV-encoded proteins during viral infection creates a favorable environment for virus
propagation and pathogenesis. In this study, we hypothesize that targeting cellular enzymes acting as master regulators of
lipid homeostasis could represent a powerful approach to developing a novel class of broad-spectrum antivirals against
infection associated with human Flaviviridae viruses such as hepatitis C virus (HCV), whose assembly and pathogenesis
depend on interaction with lipid droplets (LDs). One such master regulator of cholesterol metabolic pathways is the host
subtilisin/kexin-isozyme-1 (SKI-1) – or site-1 protease (S1P). SKI-1/S1P plays a critical role in the proteolytic activation of
sterol regulatory element binding proteins (SREBPs), which control expression of the key enzymes of cholesterol and fatty-
acid biosynthesis. Here we report the development of a SKI-1/S1P-specific protein-based inhibitor and its application to
blocking the SREBP signaling cascade. We demonstrate that SKI-1/S1P inhibition effectively blocks HCV from establishing
infection in hepatoma cells. The inhibitory mechanism is associated with a dramatic reduction in the abundance of neutral
lipids, LDs, and the LD marker: adipose differentiation-related protein (ADRP)/perilipin 2. Reduction of LD formation inhibits
virus assembly from infected cells. Importantly, we confirm that SKI-1/S1P is a key host factor for HCV infection by using a
specific active, site-directed, small-molecule inhibitor of SKI-1/S1P: PF-429242. Our studies identify SKI-1/S1P as both a novel
regulator of the HCV lifecycle and as a potential host-directed therapeutic target against HCV infection and liver steatosis.
With identification of an increasing number of human viruses that use host LDs for infection, our results suggest that SKI-1/
S1P inhibitors may allow development of novel broad-spectrum biopharmaceuticals that could lead to novel indirect-acting
antiviral options with the current standard of care.
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Introduction
Hijacking of host lipids and their biosynthetic pathways is a
common strategy for microbial infection. Human enveloped
viruses including hepatitis C virus (HCV) and human immuno-
deficiency virus (HIV)-1 use cholesterol-rich lipid rafts for entry
[1,2], assembly [3], and/or replication [2,4]. Lipid droplets (LDs),
once considered static storage vesicles for host lipids, are now
appreciated as dynamic organelles [5] that are also utilized in the
lifecycles of pathogenic human viruses including rotavirus (RV)
[6], dengue virus (DV) [7], and HCV [8]. HCV in particular
requires host LDs for assembly of nascent viral particles [9-11].
HCV is a globally important human pathogen afflicting more
than 170 million people worldwide [12,13]. HCV, a hepacivirus
member of the Flaviviridae family and an enveloped virus, is
encoded by a single-stranded positive-sense RNA genome [14].
Viral RNA is directly translated by the host machinery into a
single polyprotein, which is cleaved by host and virus-encoded
proteases to release the individual structural (core, E1, and E2) and
non-structural (NS) proteins (p7, NS2, NS3, NS4A, NS4B, NS5A,
and NS5B) [15]. During infection, HCV-encoded proteins
promote reorganization and accumulation of LDs in the
perinuclear region of the cell [16]. The HCV core protein is
targeted to LDs [17] and orchestrates the assembly and release of
infectious viral particles during the late stages of infection [18].
Hence, disrupting the interaction of the HCV core protein with
LDs compromises this essential stage within the HCV lifecycle
[8,10,11].
Several host metabolic pathways tightly control cellular lipid
synthesis. Targeted disruption of these pathways [19-21] by HCV-
encoded proteins has been linked with liver steatosis [22,23] in
HCV-infected individuals. Importantly, there is a correlation
between the degree of steatosis and both the severity of chronic
HCV infection [13,24] and the response to treatment with
pegylated-interferon-a and ribavirin [25,26].
Overstimulation of host lipid metabolism by HCV during
infection is achieved through a variety of molecular mechanisms
(reviewed in [27], [28], and [29]). For example, HCV employs
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protein (SREBP) pathway, which is important for regulation of
host lipid homeostasis [19,30–32]. SREBPs are endoplasmic
reticulum (ER), membrane-anchored transcription factors that
respond to changes in intracellular sterol levels through interac-
tions with sterol-sensing proteins (reviewed in [33]). When sterol
levels are high, SREBPs are retained as inactive precursors in the
ER [34,35]. Under low sterol conditions, SREBPs are escorted to
the Golgi, where two resident endoproteases (subtilisin kexin
isozyme/site-1 protease (SKI-1/S1P) and SREBP Site-2 protease
(S2P); reviewed in [36] and see below) cleave the precursor
polypeptide SREBP, allowing the release of transcriptionally active
SREBP molecules from the ER [37,38]. The released SREBP
fragment migrates to the nucleus and binds to sterol response
elements in the promoters of cholesterol and fatty acid biosynthetic
target genes, and it activates their transcription [39–41].
Activation of the SREBP pathway by HCV aids the virus lifecycle
and may ultimately promote the development of steatosis and liver
disease in chronically infected individuals [42,43].
Human site-1 protease (S1P, MEROPS S08.8063), also widely
known as subtilisin/kexin-isozyme-1 (SKI-1), is a membrane-
bound subtilisin-related serine endoprotease that belongs to a
group of nine mammalian proprotein convertases (PCs) in family
S08 [44–46]. SKI-1/S1P displays unique substrate specificity
among the PC members by showing preferred cleavage after
non-basic amino acids [47]. SKI-1/S1P cleaves at the carboxy-
terminus of the peptidyl sequence Arg/Lys-Xaa3-Xaa2-Leu/
Ser/Thr [48], where Xaa3 is any amino acid except Cys at the
P3 position of the scissile peptide bond and Xaa2 is a
hydrophobic amino acid containing an alkyl side chain at the
P2 position [49]. In addition to the proteolytic processing of
transcription factors [36], SKI-1/S1P participates in the
proteolytic activation of viral-envelope glycoproteins of the
Lassa virus [50], the lymphocytic choriomeningitis virus [51],
and the Crimean Congo hemorrhagic fever virus [52].
Importantly, endoproteolytic processing of these viral glycopro-
teins by SKI-1/S1P is a critical step for the production of
infectious progeny viruses, suggesting that SKI-1/S1P may
represent an attractive target for therapeutic intervention against
human pathogenic arenaviruses [47,48,50–52].
Given that SKI-1/S1P-dependent proteolytic cleavage of
SREBPs is a master molecular switch for controlling host cell
cholesterol homeostasis [41,53], we hypothesized that inhibiting
SKI-1/S1P endoproteolytic activity in the secretory pathway
would prevent HCV hijacking of host lipid metabolic pathways
and thus compromise the virus lifecycle. Because of our previous
success with engineering serine protease inhibitors (serpins) to
develop effective and selective PC inhibitors [54,55], we
hypothesized that engineering a naturally occurring serpin scaffold
could also provide a powerful approach for developing selective
SKI-1/S1P inhibitors. Serpins differ from non-serpin inhibitors in
that they require a large inhibitor conformational change in order
to trap proteases in an irreversible complex [56]. The conforma-
tional change is initiated by reaction of the active serine of the
protease with the reactive center loop (RCL) of the serpin, which
results in a covalent species involving an acyl ester linkage to the
cO of the protease active site serine [57]. This cleaves the RCL,
which then moves 71 A ˚ to the opposite pole of the serpin, taking
the tethered protease with it [57].
We selected a Drosophila serpin, Spn4A, as a prototype
macromolecular inhibitor scaffold. The identification of Spn4A
by our group as the most potent natural serpin inhibitor of the
human PC furin (Ki,13 pM [58]) provides us with a novel and
unique molecular tool for dissecting the contribution of SKI-1/
S1P-dependent proteolytic activity in the secretory pathway to
viral infection of eukaryotic cells. We report that engineering of the
RCL of Spn4A to mimic the consensus sequence Arg/Lys
P4-Xaa3-
Xaa2-Leu/Ser/Thr
P1Q for cleavage by SKI-1/S1P (Spn4A RCL:
Arg
P4-Arg-Lys-Arg
P1Q -. Arg
P4-Arg-Leu-Leu
P1Q) resulted in the
development of Spn4A-RRLL, a novel, selective, and effective
serpin-based inhibitor of SKI-1/S1P. We demonstrated the anti-
proteolytic and anti-HCV activities of our new recombinant
adenovirus-expressing Spn4A-RRLL ‘‘secreted’’ (s) variant direct-
ed at the secretory pathway SKI-1/S1P. Expression of
Spn4A.RRLL(s) in Huh-7.5.1 cells results in a strong inhibition
of the SKI-1/S1P-mediated activation of SREBP-1 and down-
regulation of SREBP target gene products. As hypothesized,
inhibiting SKI-1/S1P activity robustly blocked HCV infection of
Huh-7.5.1 cells in a dose-dependent manner. We found that
specific inhibition of SKI-1/S1P activity by Spn4A.RRLL(s)
dramatically reduced the abundance of LDs in hepatoma cells.
Use of the specific active site-directed small-molecule inhibitor of
SKI-1/S1P, PF-429242, confirmed the results of our studies with
the protein-based therapeutic Spn4A.RRLL(s), with a robust
inhibition of HCV infection.
The results of our studies contribute to our understanding of the
HCV lifecycle and HCV-associated steatogenesis and to efforts in
developing novel host-directed antiviral therapeutic agents against
HCV. In addition, with the finding that an increasing number of
human enveloped viruses employ host LDs for infection [6,7], our
results suggest that SKI-1/S1P-directed inhibitors may allow the
development of novel broad-spectrum antiviral agents.
Results
Protein engineering of the Spn4A scaffold and drug
delivery strategy to target secretory pathway SKI-1/S1P
Our previous studies have demonstrated that Spn4A architecture
can inhibit two evolutionary divergent members of the PC family
(furin and PC2) [58]. We selected this novel Drosophila melanogaster
serpin scaffold to engineer a novel protein-based inhibitor directed
at the PC SKI-1/S1P. First, we cloned our pre-His/FLAG-tagged
Author Summary
Chronic hepatitis C virus (HCV) infection is one of the
leading causes of liver cancer and liver transplantation
worldwide. No vaccine is available for preventing the
spread of HCV, and the current therapeutic regimen is only
moderately effective and causes serious side effects. New
antiviral agents are required to treat HCV infection, but the
high mutation rate of HCV hinders the effectiveness of
virus-specific inhibitors. Targeting the host enzymes
required for HCV to replicate offers a promising new
direction for antiviral therapy. During infection, HCV
promotes excessive fat accumulation in the liver, which
benefits the virus as this promotes formation of lipid
droplets, a cellular organelle essential for assembly of new
HCV infectious viral particles. Here, we report the
development of a specific inhibitor targeting SKI-1/S1P, a
host enzyme required for lipid production in human cells.
We show that inhibiting SKI-1/S1P activity in human liver
cells effectively blocks lipid droplet formation and HCV
infection. Many prevalent human viruses, such as dengue,
rotavirus, and hepatitis B virus, hijack host lipid metabolic
pathways similar to those targeted by HCV to complete
their lifecycle. Thus, we propose that cellular SKI-1/S1P is a
potential target for developing desperately needed novel
broad-spectrum antiviral drugs.
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Spn4A.RRKR(r) (Figure 1A). Spn4A is a unique ‘‘retained’’ (r)
serpin that presents, at its C-terminus, an HDEL sequence
(Figure 1A), a functional variant of the C-terminal KDEL retention
signal that directs secretory protein retention in the ER [59].
Because SKI-1/S1P cleavage of SREBP substrates occurs in the
Golgi apparatus [35], we next needed to generate a ‘‘secreted’’ (s)
variant of Spn4A, Spn4A.RRKR(s) (Figure 1A). We hypothesized
that only an Spn4A (s) variant, which traffics through the late
secretory pathway prior to secretion in the extracellular space,
would encounter active SKI-1/S1P molecules in the early Golgi
compartment. This was accomplished by inserting a stop codon
before the C-terminal ER-retention signal, HDEL. Next, we
employed site-directed mutagenesis to optimize the interactions
between the RCL of Spn4A and the substrate binding sites of SKI-
1/S1P. Residues at positions P2 and P1 of the Spn4A RCL ‘‘bait’’
region Arg
P4-Arg
P3-Lys
P2-Arg
P1Q were substituted to generate
Arg
P4-Arg
P3-Leu
P2-Leu
P1Q, thereby mimicking the Lassa virus
glycoprotein precursor GP-C cleavage site [50] (Figure 1A and 1B:
Spn4A.RRLL(r) and Spn4A.RRLL(s), respectively).
To test the serpin-like properties and antiviral activities of our
Spn4A variants in cellulo, recombinant adenoviruses (Ad) express-
ing the Spn4A constructs Ad-Spn4A.RRLL(r) and Ad-
Spn4A.RRLL(s) were produced as described previously [55]. As
adenoviruses display strong tropism for the liver [60], the major
site of HCV infection [13], these recombinant adenoviruses are
especially useful molecular tools for HCV research, including the
use of human hepatoma Huh-7.5.1 cells, which support robust
HCV infection in cellulo [61].
Robust intracellular expression and differential secretion
of adenovirus-expressed Spn4A.RRLL(r) and
Spn4A.RRLL(s) in human hepatoma Huh-7.5.1 cells
The level of expression of Spn4A variants was first optimized by
infecting human hepatoma Huh-7.5.1 cells (highly permissive for
HCV JFH-1 infection) with different multiplicity of infection (moi)
of recombinant adenovirus expressing intracellularly retained
Spn4A.RRLL(r). Cellomics HCS analysis revealed that over
90% of these Huh-7.5.1 cells expressed Spn4A.RRLL(r) at a
moi of 50 (Figure S1). Cellomics HCS was also used to determine
if cell death occurs following 2 days of pre-treatment with
Spn4A.RRLL(r) or Spn4A.RRLL(s) compared to the control (Ad-
Empty) followed by 72 hours of HCV infection as employed in the
experiments below (Figure S2). We observed no significant
reductions in total cell numbers under these experimental
conditions. The high-content analysis of cell death was confirmed
using an MTS-based cell viability assay (data not shown). The lack
of detectable toxicity induced by Ad-Spn4A.RRLL(r) and Ad-
Spn4A.RRLL(s) up to a moi of 50 showed that these variants can
be tested over a very wide dynamic range in hepatoma cells.
The serpin-secretion profile in Huh-7.5.1 cells was examined by
Western blotting of cell lysates and extracellular media. As
expected, a prominent 45-kDa band was detected in Ad-
Spn4A.RRLL(r)-infected and Ad-Spn4A.RRLL(s)-infected cell
lysates using anti-FLAG antibody (Figure 2A, lanes 2 and 3).
Furthermore, as hypothesized, the 45-kDa band of
Spn4A.RRLL(r) was found only in lysed cell extracts and was
not found secreted into extracellular media (Figure 2A, lane 2).
Conversely, the 45-kDa band of Spn4A.RRLL(s) was detected in
both whole cell extracts and in cell media (Figure 2A, lane 3).
These results confirmed the robust intracellular expression of
intact FLAG-tagged recombinant serpins (45-kDa protein band)
and the differential secretion of Spn4A.RRLL(r) and
Spn4A.RRLL(s) in Huh-7.5.1 cells.
Serpin-like properties and intrinsic specificity of
Spn4A.RRLL(r) and Spn4A.RRLL(s)
A stable, acyl-enzyme complex is formed between a protease
and a functional inhibitory serpin following RCL cleavage. This
allows for detection of the high molecular weight, heat-stable, and
SDS-stable enzyme-inhibitor (EI) complex by standard SDS-
Figure 1. Engineering the Spn4A scaffold to target the human
subtilase SKI-1/S1P. (A) Spn4A variants and amino-acid sequences of
the engineered reactive center loop (RCL) ‘‘bait’’ region are shown.
Spn4A.RRKR(r) encodes for the naturally occurring serpin Spn4A,
isolated from Drosophila melanogaster, with potent inhibitory activity
against the human proprotein convertase furin. Spn4A.RRKR(r) contains
the alpha-1 antitrypsin signal peptide (SP) at the N-terminus followed
by a tandem His-tag (HHHHHH) and FLAG-tag (DYKDDDDK) sequence
(HF). The P4 – P1 furin cleavage sequence in the RCL is Arg-Arg-Lys-Arg.
Spn4A.RRKR(r) also contains the His-Asp-Glu-Leu (HDEL) ER retention
motif (r) at the C-terminus. The secreted (s) serpin, Spn4A.RRKR(s),
contains a stop codon before the HDEL signal. The RCL of Spn4A-
RRKR(r) and (s) was modified to mimic the predicted SKI-1/S1P target
cleavage site present in the Lassa virus glycoprotein pre-GP-C, which is
Arg-Arg-Leu-Leu. Thus, Spn4A.RRLL(r), which is also retained in the ER,
encodes the P4 – P1 Arg-Arg-Leu-Leu cleavage recognition sequence in
the RCL. Spn4A.RRLL(s) contains a stop codon before HDEL, allowing
the serpin to be secreted. (B) In silico homology model of the
Spn4A.RRLL(r) variant was generated as described in the Materials and
Methods. Ribbon diagram of the molecular model was generated using
Pymol. The side chains of the RRLL residues within the flexible ‘‘bait
region’’ of the RCL are shown as sticks in wheat colour. Sheet A is
shown in yellow, sheet B is in blue, and sheet C is in cyan. Alpha-helices
are red and loops are green.
doi:10.1371/journal.ppat.1002468.g001
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Spn4A.RRLL(s) is a functional and selective inhibitor of SKI-1/
S1P, recombinant Spn4A variants (furin- and SKI-1/S1P-directed
inhibitors) were expressed in Huh-7.5.1 cells for 72 hours. Cell
media and extracts containing recombinant serpins were then
harvested and incubated with purified recombinant His-tagged
human SKI-1/S1P or furin (Figure 2B) as described previously
[47,54,58]. Reaction mixtures were analyzed by Western blot and
probed for EI complex formation with anti-His antibody
(Figure 2B) and anti-FLAG antibody (Figure S3). The results
shown in Figure 2B clearly demonstrate EI complex formation
between recombinant SKI-1/S1P and Spn4A.RRLL(s) in cell
media and in cell extracts (lane 5, upper and lower panels). As
expected, Spn4A.RRLL(s) did not form a complex with furin
(Figure 2B, lane 10, upper and lower panels), whereas the furin-
directed serpin Spn4A.RRKR(s) formed an EI complex with furin
but not with SKI-1/S1P in cell media and extracts (Figure 2B,
lanes 9 and 7, respectively, upper and lower panels). Lysed cellular
extracts expressing Spn4A.RRLL(r) also demonstrated EI complex
formation with SKI-1/S1P (Figure 2B, lane 12, bottom panel).
The results of our biochemical analysis confirmed the serpin-like
properties of recombinant Spn4A.RRLL(r) and (s) biosynthesized
in human hepatoma cells and the selectivity of Spn4A.RRLL(s)
against SKI-1/S1P. Importantly, Spn4A.RRLL(s) inhibits SKI-1/
S1P by a suicide substrate mechanism and forms a kinetically
trapped heat- and SDS-stable complex with SKI-1/S1P as is
characteristic of other physiological serpin-protease pairs [58,63].
Spn4A.RRLL(s) is a potent inhibitor of SKI-1/S1P-mediated
endoproteolytic cleavage of SREBPs, of their downstream
effector gene expression, and of intracellular
cholesterol-ester accumulation
To confirm that expression of Spn4A.RRLL(s) in Huh-7.5.1
cells inhibits endogenous SKI-1/S1P-mediated cleavage of
SREBP molecules, we examined nuclear SREBP-1 protein levels
in cells infected with adenovirus-expressed Spn4A variants. As a
positive control, we also treated cells with the selective, reversible,
and competitive small-molecule inhibitor of SKI-1/S1P: PF-
429242 [64,65]. This compound was recently synthesized and
characterized both in vitro and in vivo for its anti-lipidemic
properties including efficient inhibition of nuclear SREBP
accumulation. As previously described [64,66], the calpain
inhibitor, alpha-N-acetyl-Leu-Leu-Nle-CHO (ALLN), was em-
ployed to facilitate the detection and accumulation of the N-
terminal fragment of SREBP-1 in the nucleus. An anti-fibrillarin
antibody was used to positively identify the nuclear fractions
(Figure 3A) [67]. As expected, Western blotting of nuclear extracts
from cells treated with 10 mM of PF-429242 (PF-429242 + ALLN),
using an antibody against the N-terminal fragment of SREBP-1,
Figure 2. Cellular expression and serpin-like properties of recombinant adenovirus-expressed Spn4A variants. (A) The cellular
expression of serpin variants Spn4A.RRLL(r) and (s) were examined using infectious adenoviral-mediated expression (moi 50) in Huh-7.5.1 cells. An
empty adenovirus vector (Ad-Empty) was used as a control. After 48 hours, cell media (upper panel) and lysates (lower panels) were subjected to
Western blot analysis. Spn4A variants were detected with mouse anti-FLAG antibody and, to ensure equal loading of samples, extracts were also
probed with rabbit anti-b-tubulin antibody. (B) Huh-7.5.1 cells were infected with recombinant adenovirus expressing the His- and FLAG-tagged
Spn4A variants indicated or the Ad-Empty control for 72 hours. Media alone (upper panels) or cell extracts (lower panels) lysed in RIPA buffer were
combined with recombinant His-tagged SKI-1/S1P or His-tagged furin for 30 minutes at 30uC. Samples were prepared for Western blot analysis and
probed with mouse anti-His antibody to detect SDS- and heat-stable protease-serpin complex formation as described in the Materials and Methods.
Representative Western blots of at least 2 individual experiments are shown.
doi:10.1371/journal.ppat.1002468.g002
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nucleus (Figure 3A). Nuclear extracts from cells infected with Ad-
Spn4A.RRLL(s) (RRLL(s) + ALLN) also exhibited a dramatic
decrease in nuclear SREBP-1 accumulation when compared to
Ad-Empty (control + ALLN) and Ad-Spn4A.RRLL(r) (RRLL(r) +
ALLN)-infected cells. These results confirm that expression of
recombinant Spn4A.RRLL(s) in the secretory pathway of Huh-
7.5.1 cells inhibits SREBP-1 processing by SKI-1/S1P.
Next, to determine whether the Spn4A.RRLL(s)-mediated
reduction in nuclear SREBPs was associated with a concomitant
decrease in the protein levels in SREBP-target genes, we examined
the fate of three SREBP-dependent gene products, SREBP-2,
LDLR, and PCSK9. We investigated these host cell proteins
because of their proposed contribution to HCV entry (LDLR and
PCSK9) and propagation (SREBP-2) [19,68,69]. A time course
analysis of cells expressing Spn4A.RRLL(s) in complete media
showed the most significant block in SREBP-regulated LDLR
expression after 72 hours (Figure S4). As HCV is known to induce
SREBP activation [19,31,32], we then analyzed the expression of
SREBP-regulated proteins under SREBP-activated conditions
(Figure 3B). Huh-7.5.1 cells were depleted of exogenous sterols
for 24 hours to induce SREBP transport from ER-to-Golgi prior to
infection with Ad-Empty, Ad-Spn4A.RRLL(r), or Ad-Spn4A.
RRLL(s). The levels of LDLR, PCSK9, and SREBP-2 (all
regulated by nuclear SREBPs [70-73]) were then measured using
Western blot analysis of lysed cell extracts (Figure 3B). After 72
hours of Spn4A.RRLL(s) expression, mature LDLR (160 kDa)
levels were reduced by 74% compared to Ad-Empty-treated cells.
Figure 3. PF-429242 and Spn4A.RRLL(s) inhibit SREBP activation and reduce neutral lipid abundance in Huh-7.5.1 cells. (A) Huh-7.5.1
cells were treated with DMSO or 10 mM PF-429242 for 24 hours or infected with Ad-Empty (control), Ad-Spn4A.RRLL(r) or Ad-Spn4A.RRLL(s) for 48
hours. Cell extracts were harvested and subjected to nuclear fractionation as described in the Materials and Methods. Nuclear extracts were probed
for N-terminal SREBP-1 expression and for enrichment of the nucleolar marker, fibrillarin. The * denotes a non-specific band detected by polyclonal
anti-SREBP-1 antibody. (B) Huh-7.5.1 cells were grown in LPDS-supplemented media for 24 hours and were then infected with Ad-Spn4A.RRLL(r), Ad-
Spn4A.RRLL(s), or Ad-Empty (control) for 72 hours; cell extracts were harvested and subjected to Western blot analysis. Anti-PCSK9, LDLR, SREBP-2,
and GM130 antibodies were used to detect protein expression levels, and b-tubulin was probed for normalizing band intensities. Values are plotted
relative to protein expression in control cells (left panel). The right panel shows representative Western blots for the effect of serpin on each protein
examined. (C) Cells were treated with DMSO (control) or 10 mM PF-429242 for 24 hours. The compound was removed and the cells incubated for an
additional 24 hours. Cells were then harvested and the relative levels of intracellular lipids were determined in treated cells relative to control cells. (D)
Huh-7.5.1 cells were infected with Ad-Spn4A.RRLL(r), Ad-Spn4A.RRLL(s), or Ad-Empty (control) for 72 hours. Cells were then harvested and the relative
levels of intracellular lipids were determined in treated cells relative to the control. In (A), a representative Western blot of 3 independent experiments
is shown. For (B), (C), and (D), results (mean 6 SEM) from 3 independent experiments are shown. *p,0.05; **p,0.01; ***p,0.005.
doi:10.1371/journal.ppat.1002468.g003
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and a 79% reduction in full-length SREBP-2 expression were
observed. No significant reductions in LDLR or SREBP-2 levels
following Spn4A.RRLL(r) treatment were observed. Interestingly,
a significant reduction in PCSK9 expression was detected in
Spn4A.RRLL(r)-expressing cells (Figure 3B). The expression of b-
tubulin and of the Golgi marker GM130 were not affected by
Spn4A.RRLL(r) or Spn4A.RRLL(s) expression (Figure 3B). These
results confirm that expression of Spn4A.RRLL(s) in Huh-7.5.1
cells specifically inhibits the SREBP pathway including target
genes identified as cellular cofactors affecting HCV infection.
A critical function of the SREBP pathway and the genes that it
regulates is to control lipid homeostasis [36]. We investigated the
impact of inhibiting SKI-1/S1P using both Spn4A.RRLL(s) and
PF-429242 on total intracellular lipid levels, specifically cholester-
ol, cholesterol-esters, triglycerides, and phospholipids (Figure 3C
and 3D). Among the cell lipids examined, Spn4A.RRLL(s) and
PF-429242 had the most dramatic impact on cholesterol-ester
levels, a major constituent of cellular LDs [5]; these were reduced
by 74% in Spn4A.RRLL(s)-treated cells compared to control (Ad-
Empty)-treated cells (Figure 3C). Similarly, PF-429242 reduced
cholesterol-ester levels by , 63% compared to control cells treated
with DMSO (Figure 3D). A 14% reduction in triglycerides was
also induced by Spn4A.RRLL(s), although this reduction did not
reach significance, whereas PF-429242 caused a significant 51%
reduction in total intracellular triglycerides. A significant 5%
reduction in free cholesterol levels was also observed in
Spn4A.RRLL(s)-treated cells and a 25% reduction was observed
in PF-429242-treated cells compared to respective controls. No
significant reductions in phospholipid levels were detected
(Figure 3C and 3D). These results suggest that sustained inhibition
of SKI-1/S1P-mediated cleavage and activation of SREBP causes
increased cellular utilization of lipid stores.
Expression of secretory pathway Spn4A.RRLL(s) in
Huh-7.5.1 cells dramatically reduces the abundance of
cellular lipid storage droplets
LDs are dynamic intracellular lipid storage compartments made
up of triglyceride and cholesterol esters, surrounded by a
phospholipid membrane and associated with specific marker
proteins including adipose differentiation-related protein (ADRP),
also known as perlipin 2 [74]. Because SREBP activation controls
the expression of genes directly involved in intracellular fatty acid
and cholesterol biosynthesis (reviewed in [36]) and because
cholesterol-ester levels were reduced by Spn4A.RRLL(s), we
investigated the effect of serpin-mediated SKI-1/S1P inhibition
on cellular LD abundance. Fluorescence microscopy was used to
determine the relative abundance of LDs stained with BODIPY
493/503 in Huh-7.5.1 cells infected with Ad-Empty (control), Ad-
Spn4A.RRLL(r), and Ad-Spn4A.RRLL(s). After 72 hours, the
level of BODIPY-stained LDs in Spn4A.RRLL(s)-expressing cells
was dramatically reduced compared to empty vector-treated cells
(Figure 4A). By contrast, Spn4A.RRLL(r)-expressing cells had no
apparent reduction in LD size or abundance compared to control-
treated cells (Figure 4A). Quantification of confocal microscopy
images demonstrated that, on average, LD abundance was
reduced by 80% in Spn4A.RRLL(s)-expressing cells compared
to controls (Figure 4B). The effect of Spn4A.RRLL(s) expression
on cytosolic LD abundance was confirmed by visualizing the LD
marker ADRP/perilipin 2 using confocal microscopy (Figure 4C)
and by using quantitative Western blot (Figure 4D).
Spn4A.RRLL(s) was observed to reduce ADRP/perilipin 2
protein expression by 50% compared with control cells
(Figure 4D), whereas there was no reduction in ADRP/perlipin
2 expression following Spn4A.RRLL(r) treatment. We subse-
quently confirmed that reduced cellular LD levels were due to
inhibition of SKI-1/S1P using 10 mM PF-429242 whereupon
ADRP/perilipin 2 levels were reduced by 62% compared to
control DMSO-treated cells (Figure 4E). These results confirm
that Spn4A.RRLL(s)- and PF-429242-mediated inhibition of SKI-
1/S1P enzymatic activity dramatically reduces intracellular LD
abundance in Huh-7.5.1 cells.
Expression of secretory pathway Spn4A.RRLL(s) in
Huh-7.5.1 cells results in a dose-dependent inhibition of
HCV infection
Since the SREBP signaling pathway is induced by HCV-
encoded proteins during infection [19,30-32], we tested the effect
of inhibiting this pathway on the HCV lifecycle in human
hepatoma cells. Huh-7.5.1 cells were treated with increasing moi
(1–50) of Ad-Spn4A.RRLL(r), Ad-Spn4A.RRLL(s), or Ad-Empty
(control) for 48 hours in complete media with or without
exogenously added sterols followed by 72 hours of infection with
HCV. The number of HCV-infected cells, as evidenced by
positive core protein expression, was measured using Cellomics
HCS (Figure 5A). It was determined that Spn4A.RRLL(s)
expression inhibited HCV infection in a dose-dependent manner
compared to control-treated cells. HCV infection was not
significantly reduced in cells infected with Ad-Spn4A.RRLL(s) at
a moi of 1. A moi of 12.5, however, caused a 40% reduction, a moi
of 25 caused a 60% reduction, and a moi of 50 caused a 75%
reduction in the number of HCV-infected cells compared to
controls. Spn4A.RRLL(r) had no significant impact on HCV
infection up to adenovirus moi 50 when compared to the control
(Figure 5A). Supplementing sterol and lipid metabolites signifi-
cantly restored infectivity when cells were treated with moi 50 of
Ad-Spn4A.RRLL(s), where a 2-fold increase in HCV infection
compared to non-supplemented cells was observed (Figure 5A).
These results show that the anti-HCV activity of Spn4A.RRLL(s)
is, at least in part, associated with its capacity to decrease
intracellular lipid stores within the host cells.
The anti-HCV properties of Spn4A.RRLL(s) were confirmed
and extended by further virological studies on cells pre-treated
with our serpin-based inhibitors for 48 hours prior to 72 hours of
HCV infection (Figure 5B and 5C). First, quantitative Western
blot analysis revealed a 64% reduction in the expression of
intracellular HCV core protein in Spn4A.RRLL(s)-expressing cells
compared to the control (Figure 5B). Similarly, Spn4A.RRLL(s)
treatment was found to reduce extracellular infectious HCV titers
by 76% (Figure 5B). A 65% reduction in intracellular HCV RNA
levels was also observed using quantitative PCR (QPCR analysis
(Figure 5C). Spn4A.RRLL(r) expression did not significantly
impact any aspect of the HCV lifecycle examined (Figure 5A,
5B and 5C). These results demonstrate that inhibition of SKI-1/
S1P-mediated proteolytic activation of SREBP molecules using
secretory pathway protein-based inhibitors is an effective antiviral
strategy to robustly block HCV infection in Huh-7.5.1 cells.
Expression of secretory pathway Spn4A.RRLL(s) does not
compromise HCV replication in human hepatoma cells
To determine if a decrease in intracellular HCV RNA in
Spn4A.RRLL(s)-treated cells (Figure 5C) is due to reduced viral
replication or alternatively due to reduced HCV entry, we
examined cells transfected directly with total genomic HCV
RNA for 3 days following 48 hours of adenovirus-mediated serpin
expression. We found that under these experimental conditions,
when receptor-mediated HCV entry was bypassed, no significant
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PLoS Pathogens | www.plospathogens.org 6 January 2012 | Volume 8 | Issue 1 | e1002468Figure 4. LD abundance is dramatically reduced in Huh-7.5.1 cells expressing Spn4A.RRLL(s). (A-C) Huh-7.5.1 cells were infected with Ad-
Empty (control), Ad-Spn4A.RRLL(r), or Ad-Spn4A.RRLL(s) for 72 hours. Fixed cells were stained for cell nuclei using Hoechst dye (blue) and probed for
expression of Spn4A variants using mouse anti-FLAG antibody (red). (A) LDs were detected using BODIPY 493/503 (green), and images were acquired
using a Leica TCSSP5 confocal microscope. (B) MetaMorph imaging software was used to quantify the number of BODIPY-stained LDs in control cells
(n=23) and individual cells expressing Spn4A.RRLL(r) (n=21) or Spn4A.RRLL(s) (n=15). Acquisition and analysis were performed using the same
intensity and threshold settings across all images. (C) The LD marker ADRP was detected in cells treated with Spn4A.RRLL(r), Spn4A.RRLL(s), and Ad-
Empty (control) using rabbit anti-ADRP antibody (green), and images were obtained using an Olympus Fluoview FV1000 laser scanning confocal
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(Figure 5C). Examination of total cell extracts by Western blot
revealed that HCV core levels are not reduced following HCV
RNA transfection in serpin-treated cells (Figure S5), confirming
that Spn4A.RRLL(s) does not interfere with HCV replication
when HCV entry is bypassed.
The impact of Spn4A.RRLL(s) treatment on HCV replication
was further investigated using HCV subgenomic replicons [75].
Human hepatoma cells harbouring stable HCV replicons
encoding wild-type NS5A (Huh.8 cells) or NS5A with an adaptive
mutation (Huh.2 cells) were treated with recombinant adenovi-
ruses for 5 days. Total RNA levels were then harvested and the
level of HCV RNA was quantified using QPCR analysis. No
significant differences were observed between HCV replicon levels
treated with Spn4A.RRLL(s), Spn4A.RRLL(r), and the control
(Ad-Empty) (Figure 5D). These results confirm that Spn4A.
RRLL(s) does not inhibit HCV replication. These findings, in
addition to the measured decrease in LDLR expression presented
in Figure 3B, strongly suggest that the robust reduction in
intracellular HCV RNA levels observed in Spn4A.RRLL(s) pre-
treated cells prior to HCV infection is, at least in part, due to
reduced viral attachment or entry.
The anti-HCV properties of PF-429242
Next, we wanted to test whether extracellularly applied PF-
429242 would effectively inhibit the endoproteolytic activity of
secretory pathway SKI-1/S1P and reduce HCV infection in Huh-
7.5.1 cells. First, using an MTS-based cell viability assay, we
confirmed that no major cytotoxic effects occur in Huh-7.5.1 cells
treated with up to 50 mM of PF-429242 (Figure S6). Next, cells
were treated with increasing concentrations (0.05 mMt o5 0mM) of
PF-429242 for 24 hours before the cell media was replaced and
cells were infected for 48 hours with HCV. The number of HCV-
infected cells, indicated by positive core protein expression, was
measured using Cellomics HCS (Figure 6A, left panel). As
expected, host cell pretreatment with PF-429242 resulted in a
dose-dependent decrease in the number of HCV-infected cells
(EC50 6.461.3 mM) (Figure 6A, right panel). A near complete
block in HCV infection was observed following treatment with
40 mM of inhibitor (Figure 6A, right panel).
To examine further the impact of PF-429242 prophylactic
treatment on the different stages of the HCV lifecycle, we next
tested the effect of 24-hour PF-429242 pre-treatment on the
production of infectious progeny virions, which are normally
detected 72 hours post-HCV infection in Huh-7.5.1 cells. Under
these experimental conditions, a 16-fold reduction in extracellular
viral titers was observed (Figure 6B, left panel) with an EC50
concentration of 1.0360.3 mM. Interestingly, a single prophylactic
pre-treatment of Huh-7.5.1 cells with 40 mM PF-429242 was
sufficient to maintain a 10-fold decrease of intracellular HCV core
production 72 hours post-infection (EC50 value of 6.564.8 mM)
(Figure 6B, right panel). These results indicated that pre-treatment
of host cells with PF-429242 was sufficient to robustly block HCV
infection by preventing HCV entry and/or downstream produc-
tion of infectious progeny virions.
To elucidate the lifecycle stage compromised by treatment with
PF-429242, we tested the effect of the compound when added after
the HCV entry stage in Huh-7.5.1 cells. We hypothesized that if
only the entry stage of HCV lifecycle is blocked when SREBP
cleavage is inhibited by PF-429242, additionof PF-429242 24 hours
post-HCV infection should have no impact on the progression of
HCV infection. To test this hypothesis, cells were first infected with
HCV for 24 hours, allowing uninterrupted HCV entry and
establishment of infection. HCV-containing media was then
removed, and the cells were treated with 0.05 mMt o5 0mMo f
PF-429242. In this scenario, HCV infection was reduced by up to
78% in cells treated with 40 mM PF-429242 compared to DMSO-
treated cells (Figure 6B, right panel). Infectious virus production
(extracellular viral titer) was reduced by ,90% following treatment
with 40 mM of inhibitor (EC50 of 6.063.5 mM) (Figure 6B, right
panel). These results indicate that SKI-1/S1P inhibition also
inhibits post-entry stages of the HCV lifecycle.
Because PF-429242 and Spn4A.RRLL(s) decrease the abun-
dance of LD components, we hypothesized that HCV assembly,
rather than HCV replication, can also blocked by SKI-1/S1P
inhibition. To support this hypothesis, Huh.8 and Huh.2 cells
were treated with 10 mM PF-429242 for 72 hours. No significant
changes in HCV subgenomic RNA levels in either cell line
(Figure 6C) treated with PF-429242 were observed (compared to
DMSO-treated control). In summary, with the lack of effect of PF-
429242 on HCV replicon levels and comparing the two sets of
data presented in Figure 6B, which demonstrate a strong antiviral
effect of PF-429242 when added either pre- or post-HCV
inoculation, we can propose that pharmacological inhibition of
SKI-1/S1P endoproteolytic activity by PF-429242 impacts late
assembly stages of the HCV lifecycle.
Discussion
It is now well established that hijacking of host-cell biosynthetic
pathways by human enveloped viruses is a shared molecular event
essential for the viral lifecycle [76]. The next frontier is identifying
common,critical,hostcellpathwaysthatarehijackedbypathogenic
human viruses, in order to develop broad-spectrum, host-directed
antivirals with novel mechanisms of action. In this study, we
hypothesized that targeting cellular enzymes acting as master
regulators of lipid homeostasis could represent a powerful approach
to developing a novel class of antiviral agents against infection
associated with human enveloped viruses such as HCV, whose
replication and pathogenesis depend on the interaction with lipid
droplets (LDs) [8]. In the case of HCV, overstimulation of host lipid
metabolism in the liver during viral infection promotes cholesterol
intracellular storage in host LDs, a critical cellular event for the
HCV lifecycle that leads to steatosis of the liver in HCV-infected
patients [8,18,77]. One such master regulator of cholesterol
metabolic pathways is the host proprotein convertase SKI-1/S1P
[36,78]. SKI-1/S1P plays a critical role in the proteolytic activation
of SREBPs, which control expression of key enzymes of cholesterol
and fatty-acid biosynthesis [41,53]. Here, we report that strategic
manipulation of cellular SKI-1/S1P activity levels by protein-based
or small-molecule protease inhibitors provides a means of effectively
microscope. (D) Huh-7.5.1 cells infected with Ad-Empty (control), Ad-Spn4A.RRLL(r), or Ad-Spn4A.RRLL(s) for 72 hours were harvested and subjected
to SDS-PAGE and Western blot analysis. Mouse anti-ADRP antibody was used to detect protein expression levels in serpin-treated cells compared to
control-treated cells. Relative protein expression was quantified by normalizing to b-tubulin expression. The inset shows a representative Western
blot. (E) Huh-7.5.1 cells were treated with DMSO (control) or with 10 mM PF-429242 for 24 hours, the compound was removed, and the cell lysates
were harvested after an additional 48 hours. Relative ADRP expression (normalized to b-tubulin) in inhibitor-treated cells compared to control cells
was quantified by subjecting total cell lysates to Western blot analysis. Values are plotted relative to protein expression in control cells, which are set
to 1. Results (mean 6 SEM) from 3 independent experiments are shown. *p,0.05.
doi:10.1371/journal.ppat.1002468.g004
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PLoS Pathogens | www.plospathogens.org 8 January 2012 | Volume 8 | Issue 1 | e1002468Figure 5. Inhibition of SKI-1/S1P using Spn4A.RRLL(s) results in a dose-dependent inhibition of HCV infection in Huh-7.5.1 cells. (A)
Huh-7.5.1 cells were infected with moi (1 – 50) of Ad-Empty (control), Ad-Spn4A.RRLL(r), or Ad-Spn4A.RRLL(s) for 48 hours in regular media or media
supplemented with sterols. Treated cells were infected with HCV (moi 0.1) and fixed 72 hours post-HCV-infection. Cells, probed with HCV anti-core
antibody (red) and stained with Hoechst dye (nuclei; blue), were quantified using Cellomics HCS to determine the percentage of HCV-infected cells.
Sample images of cells infected with adenovirus moi 50 acquired with Cellomics HCS using the 10 X objective are shown below the graph. (B) Huh-
7.5.1 cells were infected with Ad-Empty (control), Ad-Spn4A.RRLL(r), or Ad-Spn4A.RRLL(s) (moi 50) for 48 hours in complete media and then infected
with HCV (moi 0.1) for 72 hours. Relative HCV-core expression (normalized to b-tubulin) in serpin-treated cells compared to control-treated cells was
quantified by examining total cell lysates using Western blot analysis. Infectious HCV titer in the extracellular media was also determined and
relatively quantified. (C) Control and serpin-treated cells were infected with HCV or transfected with genomic HCV RNA, and total cellular RNA was
harvested 72 hours later. HCV RNA levels, normalized to b-actin transcript levels, were relatively quantified in cell extracts using real-time PCR. (D)
Huh.2 and Huh.8 replicon-harbouring cells were treated with serpin-expressing and control adenoviruses for 5 days before total RNA was harvested.
HCV RNA levels, normalized to b-actin transcript levels, were relatively quantified in cell extracts using real-time PCR. All values are expressed as
relative HCV levels in serpin-treated cells compared to control-treated cells. Results (mean 6 SEM) from at least 3 independent experiments are
shown. Statistical significance was calculated for Ad-Spn4A.RRLL(r) or Ad-Spn4A.RRLL(s) infection compared to Ad-Empty infection at the same moi.
*p,0.05; **p,0.01; ***p,0.005.
doi:10.1371/journal.ppat.1002468.g005
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dependent manner. Furthermore, we reveal the common molecular
and cellular mechanisms of action of the SKI-1/S1P inhibitors and
demonstratethat they act as negative modulators of cytoplasmic LD
abundance (Figure 7), an organelle central to HCV assembly [8]
and liver steatosis.
SKI-1/S1P-directed inhibitors are a new class of lipid
droplet-modulating agents
To investigate the biological consequences of inhibiting SKI-1/
S1P endoprotease activity on biochemical pathways of lipid
homeostasis hijacked by HCV, we first employed a protein-based
inhibitor strategy. We engineered and developed a novel,
Figure 6. Inhibition of SKI-1/S1P using PF-429242 results in a dose-dependent inhibition of HCV infection, pre- and post-
establishment of viral infection in Huh-7.5.1 cells. (A) Huh-7.5.1 cells were treated with various concentrations (0.01 to 50 mM) of PF-429242 for
24 hours. The inhibitor was removed and the cells were then infected with HCV (moi 0.1) in complete media for 48 hours. Cells, probed with HCV anti-
core antibody (red) and stained with Hoechst dye (nuclei; blue), were quantified using Cellomics HCS to determine the percentage of HCV-infected
cells. The average EC50 value from 3 independent experiments is displayed above the graph. Sample images of cells treated with DMSO or 50 mM PF-
429242 acquired with Cellomics HCS using the 10 X objective are shown to the left of the graph. (B) Cells were treated with different concentrations
(0.1 to 40 mM) of PF-429242 either 24 hours before (left half of graph) or 24 hours after (right half of graph) infection with HCV (moi 0.1). At 72 hours
post-HCV infection, cells were fixed and probed with HCV anti-core antibody (red) and stained with Hoechst dye (nuclei; blue) to determine the
percentage of HCV-infected cells (core) using Cellomics HCS. Also, media from treated and HCV-infected cells was harvested and the amount of
extracellular, infectious HCV was titered (HCV titer; FFU/ml). Results (mean 6 SEM) from 3 independent experiments are shown. (C) Huh.8 and Huh.2
replicon-harbouring cells were treated with DMSO (control) or 10 mM PF-429242 for 72 hours before total RNA levels were harvested. HCV RNA levels,
normalized to b-actin transcript levels, were relatively quantified in cell extracts using real-time PCR. Results (mean 6 SEM) from 2 independent
experiments are shown. Statistical significance was calculated for PF-429242 treated cells compared to DMSO-treated cells. *p,0.05; **p,0.01;
***p,0.005.
doi:10.1371/journal.ppat.1002468.g006
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secretory pathway, SKI-1/S1P-directed serpin, Spn4A.RRLL(s).
We showed that Spn4A.RRLL(s) forms a kinetically trapped heat-
and SDS-stable complex with SKI-1/S1P molecules characteristic
of other physiological serpin-protease pairs. We then demonstrat-
ed that it blocks the SKI-1/S1P-mediated cleavage of endogenous
SREBP-1 and the expression of SREBP downstream effector gene
products (e.g., SREBP-2, LDLR, and PCSK9). The SREBP target
gene products identified in Spn4A.RRLL(s)-treated cells are
involved in lipid homeostasis and reported to participate in
HCV-host interactions. SREBP-2, along with the other SREBP
isoforms SREBP-1a and -1c, are activated by HCV-encoded
proteins or during HCV infection [19,31]. PCSK9 has been
implicated in HCV infection through its regulation of two HCV
entry factors: CD81 and LDLR [68]. Although the specific role of
LDLR in HCV infection is unclear, increasing evidence indicates
that LDLR promotes attachment and uptake of lipoprotein-
associated HCV particles into hepatocytes [29,69,79,80].
In addition to blocking SREBP-mediated up-regulation of
hepatic genes during HCV infection, we hypothesized that
blocking SKI-1/S1P endoprotease activity would also compromise
cellular lipid storage. Analysis of intracellular lipid content and
cytoplasmic LD abundance in Spn4A.RRLL(s)-expressing cells
confirmed our hypothesis. In addition, we observed a decrease in
ADRP/perilipin 2 abundance in Spn4A.RRLL(s)-expressing cells
compared to control-treated cells. The physiological role of ADRP
has yet to be fully established but it plays an important role in LD
structure and formation. Interestingly, ADRP is degraded through
the proteasome-dependent pathway during regression of lipid-
storing cells, indicating that when ADRP is not bound to LDs,
such as in SKI-1/S1P-inhibited cells, it will be susceptible to rapid
proteasomal degradation [81]. Clinical studies have demonstrated
that there is a correlation between the level of ADRP and the
degree of hepatocyte steatogenesis in humans [82]. In addition,
ADRP is found to be up-regulated in fatty liver in humans and in
mice with liver steatosis [83]. Collectively, these observations
suggest that inhibition of SKI-1/S1P offers an attractive
therapeutic target for reducing HCV-induced liver steatosis.
SKI-1/S1P is a potential target for indirect-acting antiviral
agents against HCV infection
As hypothesized, inhibiting SKI-1/S1P-mediated SREBP en-
doproteolytic cleavage events using Spn4A.RRLL(s) resulted in a
dose-dependent decrease in HCV infection. We demonstrated that
HCV core expression and HCV RNA levels are reduced in
Spn4A.RRLL(s)-expressing cells following HCV infection, leading
to a robust reduction in extracellular infectious HCV particle
release. Western blotting also confirmed that HCV core protein
post-translational processing was unaltered by serpin expression
because the size of the protein was unaltered. Supplementing
Figure 7. SKI-1/S1P is a novel potential target for indirect-acting antiviral agents against HCV infection. (1) The inactive SKI-1/S1P
zymogen is biosynthesized in the ER and traffics to the Golgi apparatus following intramolecular autocatalytic maturation of the proenzyme
[35,46,99,100]. (2) During HCV infection, the SREBP pathway is activated by a variety of molecular mechanisms [19,30–32]. (3) For SREBP to activate
genes involved in lipid biosynthesis, its N-terminal domain must be released through sequential endoproteolytic cleavage first by SKI-1/S1P and then
by S2P [37,38]. (4) The released N-terminal domain translocates to the nucleus and activates various aspects of lipid metabolism [36]. (5) Activation of
lipid biosynthesis increases LD formation where the HCV core protein localizes to orchestrate HCV assembly and subsequent secretion [8,10,16]. (6)
Biosynthesis of LDLR, a proposed receptor for HCV entry, is also activated by SREBP signaling [69,79,101]. (7) Spn4A.RRLL(s) is a secretory pathway-
expressed serpin (Figure 1). (8) Spn4A.RRLL(s) interacts and forms a covalent complex with enzymatically active SKI-1/S1P molecules (Figure 2 and S3)
in the Golgi apparatus preventing SKI-1/S1P-mediated endoproteolytic cleavage of SREBP protein (Figure 3A). (9) A small-molecule inhibitor PF-
429242 also efficiently inhibits SKI-1/S1P endoproteolytic activity (Figure 3A). (10) SKI-1/S1P inhibition blocks expression of the putative HCV
receptor, LDLR (Figure 3B and S4), and reduces HCV entry (Figure 5). (11) The expression of other SREBP-regulated genes, such as PCSK9 and SREBP-
2, are also blocked (Figure 3B). (12) Downstream lipid synthesis is interrupted resulting in overall reduced intracellular cholesterol-ester and
triglyceride abundance (Figure 3C and 3D). (12) This is then detected as a decrease in LD abundance (Figure 4), which impedes assembly and
secretion of infectious HCV particles.
doi:10.1371/journal.ppat.1002468.g007
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onate, oleate, and cholesterol resulted in an incomplete rescue of
HCV infection, suggesting that the antiviral activity of our protein-
based inhibitor cannot be explained solely by the decreased
availability of lipids in these cells. This also supports our hypothesis
that reduced LDLR levels may compromise HCV entry into
Spn4A.RRLL(s)-treated hepatocytes. LDLR, a well-established
SREBP-regulated gene, has been repeatedly shown to support
HCV entry into hepatocytes [69,80]. Also, no significant
reductions in HCV RNA levels were observed in Spn4A.
RRLL(s)-treated cells harbouring subgenomic HCV replicons or
following full-length genomic HCV RNA transfection in Huh-
7.5.1 cells. Altogether, these studies indicate that the observed
decline in HCV RNA levels following HCV infection may result
from compromised HCV entry.
To gain further insight into the different stages of the viral
lifecycle targeted by our SKI-1/S1P inhibitor, we used an active-
site-directed small-molecule inhibitor of SKI-1/S1P, PF-429242.
This pharmacologic inhibitor of SKI-1/S1P has recently been
characterized for its effectiveness in blocking cleavage of SREBP-
2, for blocking expression of SREBP-activated genes, and also for
inhibiting arenavirus glycoprotein processing [64,84]. In contrast
to our recombinant adenovirus-expressed serpins, PF-429242 can
be added extracellularly to rapidly inhibit SKI-1/S1P. This allows
us to study the biological impact of blocking SKI-1/S1P-
dependent pathways during both early and late stages of HCV
infection.
We first confirmed a reduction in abundance of neutral lipids
and ADRP/perilipin 2 expression in PF-429242-treated cells.
Then, we confirmed that inhibition of SKI-1/S1P using PF-
429242 blocks HCV infection and extracellular infectious virus
production in a dose-dependent manner. The anti-HCV activity
of PF-429242 is very robust and particularly striking. A single 24-
hour pre-treatment with the compound was sufficient to block
HCV infection, and the antiviral effect of PF-429242 was still
apparent 72 hours post-treatment. Importantly, pharmacological
treatment of already infected HCV cells resulted in a 90%
reduction of HCV virus production. Similar to Spn4A.RRLL(s)
treatment, PF-429242 did not reduce HCV RNA levels in the two
stable subgenomic replicon cell lines that were examined. This, in
combination with the observed reduction in abundance of a
central organelle (LD) involved in HCV assembly, and the
reduction in HCV particle secretion in cells treated 24 hours after
HCV inoculation, supports PF-429242 as an inhibitor of late
stages of the HCV lifecycle, i.e., during assembly or egress. Taken
all together, these results indicate that inhibiting SKI-1/S1P can
interrupt the HCV lifecycle at multiple stages of viral infection
both preventing naı ¨ve cells from becoming infected and
preventing virus release from already infected cell populations.
Thus, developing more effective active-site-directed SKI-1/S1P
small-molecule inhibitors (, nM range) with better pharmacoki-
netic properties [64] could lead to novel indirect-acting antiviral
treatment options for HCV-infected patients [42,76,85,86].
Importantly, inhibiting the SREBP pathway in HCV-infected
cells, which have exacerbated lipid production and which are
steatotic, may relieve symptoms caused by chronic HCV infection
in addition to blocking viral infection [87].
In conclusion, pharmacologic inhibition of SKI-1/S1P offers a
very promising avenue for the development of novel anti-HCV
therapeutics (Figure 7). On one hand, targeting a host cell master
molecular switch such as SKI-1/S1P with a novel class of drugs
compromising multiple stages of the virus lifecycle would have the
main advantage of making it more difficult for the virus to develop
escape mutations [86,88]. On the other hand, the toxicity issues
associated with the inhibition of host cell proteases such as SKI-1/
S1P [89] could be addressed by using adjunctive therapy,
combining our novel class of lipid-modulating agents with the
current standard of care or with the appropriate synergistic direct-
acting antivirals [85,86].
Finally, our results reveal that targeting host LD biogenesis by
inhibiting SKI-1/S1P endoproteolytic activity may have far-
reaching applications in the therapeutic treatment of other
important human Flaviviridae viruses such as dengue virus, whose
replication and pathogenesis also depend on the interaction with
lipid droplets [7].
Materials and Methods
Cell culture and reagents
Human hepatoma Huh-7.5.1 cells were kindly provided by Dr.
Francis Chisari (Scripps Research Institute, La Jolla, CA, USA)
[61]. Huh.8 (Con1/SG-Neo) cells, supporting HCV genotype 1b
subgenomic replicon, and Huh.2 (Con1/SG-Neo: S2197P) cells,
supporting replicon with NS5A adaptive mutation, were provided
by Dr. Charles Rice (The Rockefeller University, New York, NY,
and Apath, LLC, St. Louis, MO, USA) [75]. Cultured cells were
maintained in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 1% penicillin, streptomycin, glutamine, non-
essential amino acids, 4-(2-hydroxyethyl)-1-piperazineethanesulfo-
nic acid (HEPES), and 10% fetal bovine serum (FBS) (Gibco/
Invitrogen, Burlington, ON, Canada) or 10% lipoprotein-depleted
serum (LPDS) (Biomedical Technologies Inc., Stoughton, MA,
USA). Huh.8 and Huh.2 were also maintained under selection
with 750 mM Geneticin (Invitrogen). Bovine serum albumin (BSA),
saponin, cholesterol, a-mevalonic acid, lactone, and oleaic acid
were obtained from Sigma-Aldrich Corp. (St. Louis, MO, USA).
Formaldehyde, 37% w/v was obtained from Fischer Scientific
(Pittsburgh, PA, USA).
Antibodies and dyes
A mouse anti-core antibody (1:500, Abcam, Cambridge, MA,
USA) was employed for detecting HCV infection. Antibodies used
to detect cellular proteins included rabbit anti-human proprotein
convertase subtilisin/kexin type 9 (PCSK9) (1:500, Abcam), rabbit
anti-LDLR (1:250, Fitzgerald Industries International, Inc.,
Concord, MA, USA), mouse anti-SREBP-2 (1:200, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), rabbit anti-adipose
differentiation-related protein (ADRP) (1:50, Abcam), mouse
anti-ADRP (1:20, Progen, Heidelberg, Germany), rabbit anti-b-
tubulin (1:3000, Abcam), mouse anti-b-tubulin (1:500, Lab Vision
Corporation, Montre ´al, QC, Canada), mouse anti-GM130 (1:200,
BD Biosciences, Mississauga, ON, Canada), rabbit anti-SREBP-1,
clone H160 (1:200, Santa Cruz Biotechnology), and mouse anti-
fibrillarin (1:100, Abcam). Tagged proteins were detected using
mouse anti-FLAG M2 (1:500 for Western blot and 1:50 for
immunofluorescence, Sigma-Aldrich Corp.), rabbit anti-FLAG
(1:500 for Western blot and 1:50 for immunofluorescence,
Thermo Scientific, Nepean, ON, Canada), and mouse anti-His
antibodies (1:500, Applied Biological Materials, Richmond, BC,
Canada). Secondary antibodies used for immunofluorescence were
Alexa Fluor-488-conjugated or Alexa Fluor-568-conjugated don-
key anti-mouse or donkey anti-rabbit antibodies (1:100, Molecular
Probes/Invitrogen). Secondary antibodies used for Western blot
were IRDye 680-conjugated (red bands) or 800-conjugated (green
bands) donkey anti-mouse or goat anti-rabbit antibodies (1:10000,
LI-COR Biosciences, Lincoln, NE, USA). Hoechst 33258 (10 mg/
ml) and BODIPY (4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-
3a,4a-diaza-s-indacene) 493/503 (1 mg/ml, Molecular Probes/
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respectively.
HCV RNA and infectious stock production
A plasmid containing the cDNA of an HCV consensus clone
isolated from a Japanese patient with fulminant hepatitis (JFH-1)
(GenBank accession number AB047639) [91] cloned behind a T7
promoter (pJFH-1; a generous gift from Dr. Takaji Wakita,
National Institute of Infectious Diseases, Tokyo, Japan) was used
to generate genomic HCV RNA and infectious HCV stocks as
previously described in [61].
Transfection of HCV RNA
Purified HCV RNA was used to transfect Huh-7.5.1 cells as a
means of studying HCV infection independently of receptor-
mediated entry. Five micrograms of purified RNA was incubated
with 10 ml of lipofectamine 2000 (Invitrogen) in minimal essential
media (MEM) for 30 minutes. The RNA-lipid complexes were
added to cells in MEM for 16 hours; then cells were washed with
phosphate-buffered saline (PBS) and complete media was added
for the remainder of the experiment.
HCV titer determination
The amount of infectious HCV particles generated for viral
stocks or in the described experiments was determined using a
modified, previously described protocol [61]. Briefly, 1610
4 Huh-
7.5.1 cells were plated in each well of a 96-well plate and infected
with 10-fold serial dilutions of HCV-infected cell media. At 72
hours post-infection, cells were fixed and probed as described in
the ArrayScan Quantification methods section. An ArrayScan
VTI High Content Screening (HCS) Reader (Thermo Scientific)
was used to acquire images of the entire group of infected wells.
Titers were determined by manually counting foci (fluorescence
forming units (FFU)) in the lowest dilutions with positive signal.
Recombinant adenoviruses expressing His-/FLAG-tagged
serpin variants
Spn4A (GenBank Accession number NM_165496; [92]) is the
most potent and effective natural serpin of PCs identified to date
[58]. For this reason, we selected Spn4A as a prototype of a
protein inhibitor scaffold for engineering a secretory pathway SKI-
1/S1P-directed inhibitor. First, the N-terminus of Spn4A was
modified to encode the alpha-1-antitrypsin signal peptide (residues
1–24, pre-a1-AT) followed by a 6-His tag (HHHHHH) and
FLAG-tag (DYKDDDDK) sequence (HF) [58]. The Spn4A-
variants directed at furin contain the P4 – P1 cleavage sequence
[49] Arg
P4-Arg-Lys-Arg
P1Q (RRKR) in the reactive center loop
(RCL). The ER ‘‘retained’’ (r) variant of the furin-directed serpin,
designated Spn4A.RRKR(r) (Figure 1A), presents the His-Asp-
Glu-Leu (HDEL) ER retention motif at the C-terminus. A
‘‘secreted’’ (s) variant of the serpin, Spn4A.RRKR(s), was
generated by mutating the His codon in the HDEL sequence to
a stop codon. SKI-1/S1P was reported to cleave the Lassa virus
glycoprotein sequence Arg
P4-Arg-Leu-Leu
P1Q (RRLL) [50]. Thus,
to specifically target this enzyme, we altered the furin-directed
RCL sequence to RRLL through site-directed mutagenesis using
QuikChange (Stratagene, La Jolla, CA, USA) to generate
Spn4A.RRLL(r) and Spn4A.RRLL(s) (Figure 1A and 1B). To
produce Ad-Spn4A.RRKR(s), Ad-Spn4A.RRLL(r), and Ad-
Spn4A.RRLL(s), all Spn4A constructs were cloned into adenovirus
vectors (pShuttle) [55] and then were amplified by ViraQuest Inc.
(North Liberty, IA, USA). Adenovirus titers were determined in
human embryonic kidney (HEK293T) cells using an Adeno-X
Rapid Titer kit (Clontech, Mountain View, CA, USA) [55].
Empty adenovirus (Ad-Empty), which was kindly provided by Dr.
Jan Breslow (The Rockefeller University, New York, NY, USA)
[93], was amplified by Viraquest Inc.
In silico homology model of Spn4A.RRLL variant
The Drosophila melanogaster Spn4B sequence (GeneBank Acces-
sion number gi|24586105|ref|NP_524955.2) exhibits 34% se-
quence homology with the human neuroserpin (hNS), for which a
crystal structure is available [94] in the Protein Data Bank (PDB
ID: 3F5N). Of the five chains in this pentameric structure of hNS,
chain B is most well resolved with the fewest missing residues, and
it was used as the template for the homology model presented in
Figure 1B. The model was built and refined using the SwissPDB
Viewer. The C-alpha residues in this model structure align to 1.9
A ˚ RMSD with reference to the hNS structure.
Recombinant PCs and enzymatic assays
The first 997 amino acids of human SKI-1/S1P lacking the C-
terminal transmembrane domain but containing a C-terminal 8-
His-tag (PGDDDDKHHHHHHHHSGS) were expressed in Sf9
insect cells as previously described [47]. Two liters of cell culture
supernatant were used for purification. Two hundred milliliters of
200 mM Tris/HCl pH 8.0, 500 mM NaCl was added, and then
the pH was adjusted to pH 8.0 by further addition of 2 M NaOH.
The resulting precipitate was removed by centrifugation at 10000
x g for 30 minutes and subsequently filtered through a glass filter.
The cleared supernatant was then applied to a small (0.9 ml
column volume) IMAC column (Ni-Sepharose, GE Healthcare,
Freiburg, Germany) by continuous flow (1.0 ml/minutes). The
column had previously been equilibrated in 50 mM Tris/HCl
pH 8.0, 500 mM NaCl (buffer A), and bound recombinant SKI-
1/S1P was eluted with a continuous gradient over 30 column
volumes to buffer A plus 300 mM imidazole. Collected fractions
were assayed for SKI-1/S1P enzymatic activity as previously
described [47] using the paranitroanilide (p-NA) acetylated (Ac)
tetrapeptidyl substrate Ac-RRLL-pNA [custom synthesized by
Peptides International (Louisville, Kentucky, USA)]. The most
active fractions were pooled. Concentration and buffer exchange
to buffer A was then done using spin concentrators (Millipore,
Billerica, MA, USA) with a molecular weight cutoff of 30 kDa.
The final preparation was, after addition of 30% v/v glycerol,
stored at -80uC and had a specific activity of 0.018 U/mg
(measured as above). Recombinant His-tagged furin (0.432 mg/
ml) was purchased from R & D Systems (Minneapolis, MN, USA),
and reactions with adenovirus recombinant serpin were performed
under the buffer conditions for furin assays as previously described
[54,58].
Western blot analysis
Cultured cells were washed with ice-cold PBS and re-suspended
in cold radioimmunoprecipitation assay (RIPA) buffer (50 mM
Tris-HCl pH 8, 150 mM NaCl, 1% octylphenyl-polyethylene
glycol [IGEPAL], 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate [SDS] containing 1 X Complete, EDTA-free,
protease inhibitor cocktail [Roche, Laval, QC, Canada]). Whole
cell extracts were vortexed and then clarified by centrifugation at
12000 x g for 15 minutes. Soluble extracts mixed with 2 X sample
buffer (62.5 mM Tris-HCl, pH 6.8, 25% glycerol, 2% SDS,
0.01% bromophenol blue, and 5% beta-mercaptoethanol) were
electrophoresed on 8–15% SDS polyacrylamide gels and trans-
ferred to nitrocellulose membranes. Membranes were blocked in
Odyssey blocking buffer (LI-COR Biosciences) for one hour, and
proteins of interest were detected by probing with the appropriate
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buffer containing 0.1% Tween 20. Protein bands were detected
and quantified using the Odyssey Infrared Imaging System (LI-
COR Biosciences). All immunoblots were scanned at a wavelength
of 700 nm for detecting IRDye 680 labeled antibodies and at a
wavelength of 800 nm for IRDye 800CW conjugated antibodies
[95,96]. Signal intensities were quantified by means of the Odyssey
software version 3.0. Beta-tubulin was always used as a loading
control and for normalizing protein expression. Media samples
analyzed for secreted Spn4A variants were taken directly from
cultured cells, mixed with 2 X sample loading buffer, and
subjected to the described Western blot analysis.
Stable covalent acyl-enzyme complex (EI) formation
between serpin variants and PCs
Huh-7.5.1 cells were plated at 5610
5 cells per well in a 6-well
plate and infected after 24 hours with Ad-Spn4A.RRLL(s), Ad-
Spn4A.RRLL(r), Ad-Spn4A.RRKR(s), or Ad-Empty at moi 50.
After 72 hours, media and cell extracts (harvested in hypotonic
buffer containing 20 mM Tris, pH 7.4, 10 mM MgCl2, and
10 mM CaCl2) were mixed 1:1 with enzyme reaction buffer (SK1-
1/S1P buffer contains 25 mM Tris-HCl, 25 mM MES, pH 7.4,
2.5 mM CaCl2 [47]; furin buffer contains 100 mM HEPES,
pH 7.5, 1 mM CaCl2, 0.5% Triton X-100 [54,58], 1 X Complete
EDTA-free protease inhibitor cocktail), and 11.6 ng/ml SKI-1/
S1P or 2.4 ng/ml furin. The enzyme mixture was incubated at
30uC for 30 minutes, and the reaction was stopped with 12.5 mM
EDTA (final concentration). After completion, products were
resolved on a 10% SDS-gel. The high-molecular weight band (EI)
was visualized as described above for Western blotting.
ArrayScan quantification
In black flat-bottom 96-well plates (BD Biosciences), cells were
plated (.10,000 cells/well) and infected as described in the
methods below. Following infection, cells were fixed in 4%
formaldehyde v/v diluted in PBS and blocked in PBS containing
3% BSA, 0.3% Triton X-100, and 10% FBS. Cells were first
probed with HCV anti-core antibody (1:500) in PBS containing
3% BSA and 0.3% Triton X-100 (Binding Buffer), then incubated
with Alexa Fluor-568-conjugated donkey anti-mouse secondary
antibody (1:1000) and 10 mg/ml Hoechst dye. Cells were analyzed
by a quantitative, high-throughput, fluorescence microscope
system called the Cellomics ArrayScan VTI High Content
Screening (HCS) Reader (Thermo Scientific) using the software
Target Activation BioApplication (TABA). TABA was used to
count the total number of cells (Hoechst-stained nuclei) and the
percentage of those cells that were expressing HCV core (positive
signal at 568 nm wavelength).
Nuclear fractionation
On Day 1, 2.5610
6 Huh-7.5.1 cells were plated into 100 mm
plates. On Day 2, cells were infected with recombinant
adenoviruses expressing Spn4A.RRLL(r) or Spn4A.RRLL(s), or
with Ad- Empty (moi 50). On Day 3, separate cells were treated
with the inhibitor PF-429242 or the control DMSO. On Day 5, all
samples (except the untreated control) were treated for 1 hour with
25 mM a-N-acetyl-Leu-Leu-Nle-CHO ((2S)-2-[[(2S)-2-acetamido-
4-methylpentanoyl]amino]-4-methyl-N-[(2S)-1-oxohexan-2-yl]pen-
tanamide) (Sigma-Aldrich Corp.). Nuclear fractionation of cell
lysates was performed at 4uC as described previously with
modifications [64,66]. Cells were harvested in 400 ml buffer C
(10 mM HEPES/KOH, pH 7.6, 10 mM KCl, 1.5 mM MgCl2,
1 mM EDTA, 1 mM EGTA, 250 mM sucrose) containing 1 X
complete protease inhibitor cocktail (Roche). To shear DNA, the
cells were passed 20 times through a 23-gauge needle. The lysate
was centrifuged at 1100 x g for 7 minutes and the resulting
supernatant was centrifuged again at 25000 x g for 60 minutes to
obtain the membrane pellet. The pellet containing membrane-
bound SREBP-1 was re-suspended in 75 ml of SDS-lysis buffer
(10 mM Tris HCl, 100 mM NaCl, 1% SDS, 1 mM EDTA, 1 mM
EGTA, pH 6.8). The pellet from the 1100 x g spin was re-
suspended in 100 ml buffer D (20 mM HEPES/KOH, 420 mM
NaCl, 1.5 mM MgCl2, 2.5% glycerol, 1 mM EDTA, 1 mM
EGTA, pH 7.6) containing 1 X complete protease inhibitor
cocktail. Nuclear pellets were rocked for 1 hour, after which the
samples were centrifuged at 25000 x g for 60 minutes to obtain the
clarified supernatant containing the nuclear fraction.
Confocal microscopy and immunofluorescence
After Huh-7.5.1 cells were seeded onto coverslips for 24 hours,
they were infected with adenovirus (moi 50) for 72 hours. Cells
were fixed in 4% v/v formaldehyde in PBS, then permeabilized
and blocked in PBS containing 0.05% saponin (wash buffer) and
1% BSA (binding buffer). Blocking of cells stained with BODIPY
493/503 was done in the presence of 0.2 M glycine to reduce
background fluorescence. Cells were probed with primary
antibodies in binding buffer, then incubated with a secondary
antibody, Hoechst dye (10.0 mg/ml), and BODIPY 493/503
(1.0 mg/ml; when indicated) diluted in PBS. Cells were mounted
onto slides with an anti-fade solution and sealed with clear nail
polish. The slides were then imaged using a Leica TCS SP5
confocal microscope (Leica Microsystems, Wetzlar, Germany) or
an Olympus Fluoview FV1000 laser scanning confocal microscope
(Olympus Corporation, Tokyo, Japan) [95–97]. Leica MM AF
Software (Leica Microsystems) was used to count the number of
LDs (green channel) in cells expressing Spn4A.RRLL(r) (n=21) or
Spn4A.RRLL(s) (n=15) (cells positive in the red channel). LDs in
cells treated with Ad-Empty (n=23) were also enumerated. All
quantified images were acquired using the same laser intensity and
gain settings, and LDs were enumerated by applying the same
threshold setting to each image.
Adenovirus infections
Huh-7.5.1 cells were infected with recombinant adenovirus at
different moi in complete media with or without exogenous sterols
(50 mM sodium mevalonate, 20 mM sodium oleate, 5.0 mg/ml
cholesterol). After 48 hours, the cells were infected with HCV moi
0.1 or transfected with purified HCV genomic RNA for 72 hours,
and then cells were analyzed by Cellomics ArrayScan HCS, or
total RNA was isolated from cell extracts using the RNeasy plus kit
(Qiagen, Mississauga, ON, Canada) including on-column DNase
digestion. Media from treated and infected cells were harvested for
HCV titer determination as described above. To examine the
Spn4A.RRLL(s) mediated block in PCSK9, LDLR, and SREBP-2
expression, Huh-7.5.1 cells were grown in media supplemented
with LPDS for 24 hours, infected with adenovirus variants, and
harvested 72 hours later.
Quantitative real-time (Q) PCR
Purified total RNA was reverse transcribed to cDNA using
TaqMan reverse transcription reagents (random hexamers;
Applied Biosystems, Foster City, CA, USA). Real-time quantita-
tive PCR was carried out using Brilliant II Fast QPCR reagents
(Stratagene, La Jolla, CA, USA) according to the manufacturer’s
instructions on an Mx3005P QPCR system (Stratagene). Online
ProbeFinder software (Roche Applied Science) was used to find
primers that would allow amplification of the HCV RNA 59 end in
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Roche (Roche Applied Science). For amplification of the HCV
RNA 59 region, 400 nM of both forward primer (59-CAT-
GGCGTTAGTATGAGTGTCG-39) and reverse primer (59-GG-
TTCCGCAGACCACTAT-39) were used in combination with
200 nM of probe #75 from the Human Probe Library (Roche).
HCV RNA levels were relatively quantified across samples and
normalized to beta-actin RNA levels using 500 nM primers
(forward: 59- GCC CTG AGG CAC TCT TCC and reverse: 59
GGA TGT CCA CGT CAC ACT TC-39) and 250 nM probe
(59AC TCC ATG CCC AGG AAG GAA GGC-39 with a 59 Cy5
fluorophore and 39 black hole quencher).
Cytotoxicity assay
Cell viability was determined using CellTiter 96 AQueous One
Solution Cell Proliferation Assay (Promega, Madison, WI, USA).
Thisassayemploysa tetrazoliumcompound [3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt; MTS], which is bio-reduced by cells into a colored
formazan product that can be detected in tissue culture media at
490 nm wavelength [98].
Treatment with PF-429242
PF-429242, an active site-directed small-molecule inhibitor of
SKI-1/S1P [64,84], was synthesized by Dr. Peter Chua at the
Center for Drug Research and Development (CDRD) at the
University of British Columbia (Vancouver, BC, Canada)
according to previously described protocols [65]. To investigate
the antiviral activity of the small molecule, Huh-7.5.1 cells were
treated with PF-429242 for 24 hours. After 24 hours of treatment,
the media was removed and then cells were infected with HCV
(moi 0.1) for 48 or 72 hours. Alternatively, cells were first infected
with HCV for 24 hours; then, the media was removed and
replaced with media containing various concentrations of PF-
429242 for a further 48 hours. Intracellular HCV infection levels
were determined using Cellomics HCS ArrayScan. Infectious
extracellular titers were determined in media of 72-hour HCV-
infected cells.
Intracellular lipid quantification
To measure the level of intracellular lipids following 72-hour
recombinant adenovirus expression or 48-hour PF-429242
treatment, cellular extracts were harvested in 1% triton-X 100
in PBS (for phospholipid, cholesterol, and protein assay) or 5%
triton-X 100 in H2O (for triglyceride assay). To extract
triglycerides, samples were slowly heated to 90uC and brought
to room temperature, twice. Total cholesterol, cholesterol esters
(Amplex Red Cholesterol Assay kit, Invitrogen), phospholipids,
and triglycerides (EnzChrom, BioAssay Systems, Hayward, CA,
USA) were quantified using commercially available kits. Lipid
levels were normalized to cellular protein content (DC Protein
Assay, Bio-Rad, Hercules, CA, USA).
Curvefitting, half-maximal effective concentration (EC50)
determination and statistics
The sigmoidal fit function in Igor Pro software (WaveMetrics,
Inc., Portland, OR, USA) was used for fitting HCV and PF-429242
inhibition curves and for determining EC50 values. The reported
EC50 values are the average of the values calculated from three
independent experiments plus or minus the standard deviation. The
student’s t-test (unpaired) was used to calculate significance, which is
represented in the figures by the following notation: * denotes
p,0.05, ** denotes p,0.01, and *** denotes p,0.005.
Supporting Information
Figure S1 Optimization of adenovirus-expressed
Spn4A.RRLL(r) expression in Huh-7.5.1 cells. Huh-7.5.1
cells were infected with moi 1, 12.5, 25, and 50 of the
intracellularly retained serpin Ad-Spn4A.RRLL(r). Treated cells
were fixed 48 hours post-infection and probed for serpin
expression using mouse anti-FLAG antibody. Cell nuclei were
stained with Hoechst dye to determine the total cell number. The
percentage of Spn4A.RRLL(r)-expressing cells was quantified
using Cellomics HCS. Results (mean 6 SEM) from 2 independent
experiments are shown.
(TIF)
Figure S2 Effect of Spn4A variant treatment and HCV
infection on Huh-7.5.1 cell growth. Huh-7.5.1 cells were
infected with various moi (1 – 50) of Ad-Empty, Ad-
Spn4A.RRLL(r), or Ad-Spn4A.RRLL(s) for 48 hours in complete
media. Treated cells were infected with HCV (moi 0.1) and fixed
72 hours post-infection. Fixed cells were probed with Hoechst dye
to stain for cell nuclei, which were then quantified using Cellomics
HCS to determine the relative number of cells in each well under
the varying conditions. All values are expressed as relative cell
number in serpin-treated cells compared to cells infected with Ad-
Empty, which is set to 1. Results (mean 6 SEM) from 3
independent experiments are shown.
(TIF)
Figure S3 Serpin-like properties of recombinant ade-
novirus-expressed Spn4A variants expressed in Huh-
7.5.1 cells. Huh-7.5.1 cells were infected with recombinant
adenovirus expressing the His- and FLAG-tagged Spn4A variants
indicated or the Ad-Empty control for 72 hours. Media alone
(upper panels) or cell extracts (lower panels) lysed in RIPA buffer
were combined with recombinant His-tagged SKI-1/S1P [47] or
His-tagged furin for 30 minutes at 30uC. Samples were prepared
for Western blot analysis and probed with rabbit anti-FLAG
antibody to detect SDS- and heat-stable protease-serpin complex
formation and also to distinguish serpin bands from protease
bands on the Western blots. All Western blots shown are
representative of at least 2 independent experiments.
(TIF)
Figure S4 Time course analysis of LDLR expression in
Spn4A.RRLL(s)-treated cells. Huh-7.5.1 cells were grown in
complete media for 24 hours and then infected with Ad-Empty
(control) or Ad-Spn4A.RRLL(s). Cell extracts were harvested for
Western blot 24, 48, and 72 hours post-infection, and lysates were
then subjected to Western blot. Anti-LDLR antibody was used to
detect protein-expression levels in control- and Ad-Spn4A.
RRLL(s)-treated cells, and b-tubulin was probed for normalizing
LDLR expression. Values are plotted relative to LDLR expression
in control (Ad-Empty)-treated cells, which was set to 1. The
representative results of 2 independent experiments are shown.
(TIF)
Figure S5 Spn4A.RRLL(s) does not block HCV core
production post-transfection of HCV RNA. Huh-7.5.1 cells
were infected with Ad-Empty (control), Ad-Spn4A.RRLL(r), or
Ad-Spn4A.RRLL(s) (moi 50) for 48 hours in complete media and
then transfected with genomic HCV RNA for 72 hours. Relative
HCV-core expression (normalized to b-tubulin) in serpin-treated
cells compared to control-treated cells was quantified by
examining total cell lysates using Western blot analysis. Results
(mean 6 SEM) from 2 independent experiments are shown. A
representative Western blot is shown to the right of the graph.
(TIF)
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7.5.1 cells were treated with DMSO (control) or various
concentrations of PF-429242 for 24 hours before the inhibitor
was removed, and fresh complete media was added to the cells for
an additional 48 hours. The relative cytotoxicity of the compound
was then determined using an MTS-based cell viability assay. The
absorbance measured at 490 nm is proportional to the number of
living cultured cells. Results (mean 6 SEM) from 3 independent
experiments are shown. Statistical significance was calculated for
PF-429242-treated cells compared to DMSO-treated cells.
(TIF)
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